{"filing":{"accession_number":"0001193125-26-384472","cik":"0001830487","ticker":"PHVS","company_name":"Pharvaris N.V.","form":"6-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"corp_presentation_sept_2.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1830487/000119312526384472/corp_presentation_sept_2.htm"},"events":[{"id":31861,"run_id":29260,"accession_number":"0001193125-26-384472","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.25,"summary":"This exhibit is a clinical trial data presentation for CHAPTER-3 Phase 3 study of deucrictibant XR for long-term prophylaxis of hereditary angioedema (HAE). While it discloses positive topline results (83% attack rate reduction vs. placebo, p\u003c0.0001, all secondary endpoints met, well-tolerated safety profile), it is not a financial earnings release but rather a clinical/scientific presentation of investigational drug trial outcomes. The document explicitly states \"This presentation includes data for an investigational product not yet approved by regulatory authorities\" and focuses on efficacy, safety, and quality-of-life endpoints rather than financial results. However, for a clinical-stage biopharmaceutical company, positive Phase 3 data is material to investors' assessment of the company's prospects and regulatory pathway.","company_name":"Pharvaris N.V.","ticker":"PHVS","filing_date":"2026-09-08","form":"6-K","submitted_at":null,"items":[{"id":34886,"accession_number":"0001193125-26-384472","item_number":"EX-99.1","item_title":"phvs-ex99_1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.25,"reasoning":"This exhibit is a clinical trial data presentation for CHAPTER-3 Phase 3 study of deucrictibant XR for long-term prophylaxis of hereditary angioedema (HAE). While it discloses positive topline results (83% attack rate reduction vs. placebo, p\u003c0.0001, all secondary endpoints met, well-tolerated safety profile), it is not a financial earnings release but rather a clinical/scientific presentation of investigational drug trial outcomes. The document explicitly states \"This presentation includes data for an investigational product not yet approved by regulatory authorities\" and focuses on efficacy, safety, and quality-of-life endpoints rather than financial results. However, for a clinical-stage biopharmaceutical company, positive Phase 3 data is material to investors' assessment of the company's prospects and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T13:02:01.620401+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34886,"accession_number":"0001193125-26-384472","item_number":"EX-99.1","item_title":"phvs-ex99_1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.25,"reasoning":"This exhibit is a clinical trial data presentation for CHAPTER-3 Phase 3 study of deucrictibant XR for long-term prophylaxis of hereditary angioedema (HAE). While it discloses positive topline results (83% attack rate reduction vs. placebo, p\u003c0.0001, all secondary endpoints met, well-tolerated safety profile), it is not a financial earnings release but rather a clinical/scientific presentation of investigational drug trial outcomes. The document explicitly states \"This presentation includes data for an investigational product not yet approved by regulatory authorities\" and focuses on efficacy, safety, and quality-of-life endpoints rather than financial results. However, for a clinical-stage biopharmaceutical company, positive Phase 3 data is material to investors' assessment of the company's prospects and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T13:02:01.620401+00:00","company_name":"Pharvaris N.V.","ticker":"PHVS","filing_date":"2026-09-08"}]}